Dr Reddy's Laboratories (DRL) has initiated voluntary recall of Rivastigmine Tartrate Capsules of 1.5 mg strength from the USA market, following 'Failed Dissolution Specifications'. A total of 60 bottles of 2952 units are recalled on the direction of US Food and Drug Administration (USFDA). According to a notification issued by the agency, the batch was manufactured at DRL's Ltd, Bachupally unit and the recall was initiated under "Class II" classification. Rivastigmine Tartrate Capsules are indicated for the treatment of mild to moderate dementia of the Alzheimer's type or Parkinson's disease. ALSO READ: Dr Reddy's looking at adding its might to start-ups in allied areas: G V Prasad According to the US health regulator, Class II recall is a situation in which the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Shares of Dr Reddy's traded at Rs 4,308 apiece, up 1.80 per cent over previous close on BSE .
About Money99
Parag Patil is a technical analyst and trading system designer with stock excel programmer. I hope the articles and live chart of nse future and mcx on this Website will be as helpful and profitable to you . I try to update and post new articles tips everyday. My motto is to encourage the traders, so that they should able to understand the technique views behind the moment of stocks. I have deeply analyzed with many technical indicator with parameter and added to my amibroker afl. And even taken backtest report which is never being implemented. Any of the analyst expect me. Seeing all this you may understand that my views is more technical than commercial. If you are profited by my views I fill happy.
0 comentários:
Post a Comment